The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively chelated iron from Rhizopus oryzae and demonstrated cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentrations well below clinically achievable serum levels. When administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decreased tissue fungal burden, with an efficacy similar to that of liposomal amphotericin B. Deferasirox treatment also enhanced the host inflammatory response to mucormycosis. Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B. These data support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of mucormycosis with current therapy. As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This pathway appears to be partly responsible for the beneficial clinical effects of iron chelators observed in several experimental infection systems (Mencacci et al., 1997; Fritsche et al., 2001; Ibrahim et al., 2007; Bellmann-Weiler et al., 2013; Nairz et al., 2013).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Ibrahim et al., 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the Fe chelator desferasirox, which cannot be used by molds to acquire Fe, improves survival of infected mice, limiting Fe availability to the pathogen while enhancing host resistance mechanisms [238].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Schaible, U. E., & Kaufmann, S. H. E. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1046 · Cited by 945
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717 · cited 2×
“Furthermore, it is known that deferasirox chelation is specific for iron and that other trace metals and cations are not affected by the drug (27, 28).”
Zygomycosis in the 1990s in a Tertiary-Care Cancer Center
Kontoyiannis, D. P., Wessel, V. C., Bodey, G. P., & Rolston, K. V. I. (2000) · Clinical Infectious Diseases · doi:10.1086/313803 · Cited by 521
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369 · cited 2×
“Alternatively, the enhanced efficacy of deferasirox in the diabetic ketoacidotic mouse model might reflect the ability of this iron chelator to efficiently chelate serum iron previously freed by proton-mediated dissociation from iron-sequestering proteins (2, 16, 17).”
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340 · cited 2×
“The potential therapeutic role of iron chelation therapy for mucormycosis was initially obscured by the paradoxically increased risk of developing mucormycosis during treatment with deferox-amine (18).”
Research works printed but not linked: 4
- Ganz, 2006, Curr. Top. Microbiol. Immunol., 306, 183
- Artis, 1982, Diabetes., 31, 1109, 10.2337/diacare.31.12.1109 · doi:10.2337/diacare.31.12.1109 · Paper page
- Fu, 2004, FEMS Microbiol. Lett., 235, 169
- Ibrahim, A.S., et al. 2000. Comparison of amphotericin B and amphotericin B lipid complex in the treatment of murine-induced zygomycosis. In 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17–20. Toronto, Ontario, Canada. American Society of Microbiology. Abstract 1681.
Cited by
Items 201–300 of 327
Extrapolating Antifungal Animal Data to Humans—Is It Reliable?
Stevens, V. M., Mueller, S. W., Reynolds, P., MacLaren, R., & Kiser, T. H. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00370-x · Cited by 12
Chen, Y., He, Y., Zhou, H., Wang, M., & Sheng-ou, S. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4074 · Cited by 11
“In addition, multiple lines of evidence supported a link between iron availability and the risk of mucormycosis (4).”
Animal Models In Mycology: What Have We Learned Over The Past 30 Years
Kirkpatrick, W. R., Wiederhold, N. P., Najvar, L. K., & Patterson, T. F. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0126-6 · Cited by 11
Silva-Gomes, R., Caldeira, I., Fernandes, R., Cunha, C., & Carvalho, A. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae045 · Cited by 10
Spellberg, B. J., & Maertens, J. A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_34 · Cited by 10
Self-citationA Comprehensive Review on the Management of COVID-19-Associated Mucormycosis (CAM): The New Basics
Girdhar, D., & Manocha, E. (2022) · BioMed · doi:10.3390/biomed2020017 · Cited by 10
Kim, D., Cho, H. S., Kang, J.-I., Kim, H. S., & Park, C. Y. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.08.003 · Cited by 10
“Recently, there have been a few case reports in which, Mucorales for which iron availability is critical for growth, was successfully treated with deferasirox.(16,17) Based on these case reports, our patient was given deferasirox instead of deferoxamine in combination with antibiotics in order to depress the growth of…”
BackgroundÜnal, Ş., Kuşkonmaz, B., Hazırolan, T., Eldem, G., Aytaç, S., Çetin, M., Uçkan, D., & Gümrük, F. (2010) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2010.493573 · Cited by 9
“On the other hand, deferasirox has recently been reported to be beneficial in mucormycosis in both human and animal models [17, 18].”
BackgroundAbolhasani, J., Naderali, R., & Hassanzadeh, J. (2016) · Analytical Sciences · doi:10.2116/analsci.32.381 · Cited by 9
Uppuluri, P., Alqarihi, A., & Ibrahim, A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21013-3 · Cited by 9
Self-citationExperimental Models to Study the Pathogenesis and Treatment of Mucormycosis
Ben‐Ami, R. (2024) · Journal of Fungi · doi:10.3390/jof10010085 · Cited by 8
“Although the Drosophila model is not suitable for precision pharmacokinetic experiments, simple pharmacologic interventions can be performed by adding drugs to fly feed [19,27,34,86].”
BackgroundMethodInfluentialTreatment of Non-Aspergillus Mold Infections: a Focus on Mucormycosis and Fusariosis
Phoompoung, P., & Luong, M. (2019) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-019-00205-5 · Cited by 8
Itoh, K., Tsutani, H., Mitsuke, Y., & Iwasaki, H. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1210747 · Cited by 7
Jong, T., Stack, C. M., Moffitt, M. C., & Morton, C. O. (2025) · Pathogens · doi:10.3390/pathogens14040335 · Cited by 7
“Other therapeutic Fe-chelating agents developed and incapable of being used as siderophores by Mucorales fungi have been shown to be protective in animal infection models [118].”
Velumani, K., Arasu, A., Issac, P. K., Kumar, M. S. K., Guru, A., & Arockiaraj, J. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08882-8 · Cited by 7
“In vivo and in vitro investigations revealed that deferasirox causes iron deficiency in Mucorales, implying that using this as an adjuvant can inhibit fungal dispersion [44].”
BackgroundTargeting Ferroptosis: A Novel Strategy for the Treatment of Atherosclerosis
Zhang, Y., Jiang, C., & Meng, N. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575273164231130070920 · Cited by 7
Shakri, A. R., Zhong, T. J., Ma, W., Coker, C., Hegde, R., Scholze, H., Chin, V., Szabolcs, M. J., Hibshoosh, H. H., Tanji, K., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3242 · Cited by 7
Arias-León, G., & Herazo, J. G. (2010) · Infectio · doi:10.1016/s0123-9392(10)70135-1 · Cited by 7
Combination antifungal therapy: From bench to bedside
Wirk, B. M., & Wingard, J. R. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0007-1 · Cited by 7
A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori
Ishii, M., Mikami, K., Tabuchi, F., Maruyama, N., & Miyashita, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333476 · Cited by 6
“Dosages were selected based on previously reported studies using Galleria mellonella and murine mucormycosis models [31,32].”
Babu Anand, C., Senthilkumar, S., Nivedha, P., Mohammed Ibrahim, C., Khizer Hussain Afroze, M., & Ramanathan, M. (2022) · Cureus · doi:10.7759/cureus.24013 · Cited by 6
“As a result, the relationship between iron and ferritin concentrations and mortality may indicate increased baseline iron storage in patients, leading to more severe infection, underlying illness, or both [11-15].”
BackgroundImpact of iron chelators on growth and expression of iron-related genes of Cryptococcus species
Chayakulkeeree, M., Tangkoskul, T., Waywa, D., Tiengrim, S., Pati, N., & Thamlikitkul, V. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.100905 · Cited by 6
Singh, A., Pandey, S., Singh, S., & Kumar, N. (2015) · International Journal of Health & Allied Sciences · doi:10.4103/2278-344x.160890 · Cited by 6
“B against Glomeromycota.”
BackgroundWalsh, T. J., Roilides, E., Rex, J. H., & McGinnis, M. R. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3935-5.00089-6 · Cited by 6
Treating mucormycosis using a multimodality approach: a case series
Gupta, A. K., Parwal, C., Mangal, M., Gambhir, S. S., Nanda, B. S., & Sarangi, K. (2018) · Journal of Wound Care · doi:10.12968/jowc.2018.27.11.735 · Cited by 6
Treatment of pulmonary mucormycosis: current concepts
Muthu, V., Sehgal, I. S., & Agarwal, R. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2622695 · Cited by 5
Tanwar, M., Singh, A., Singh, T. P., Sharma, S., & Sharma, P. K. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00082 · Cited by 5
Calera, J. A., & Haas, H. (2014) · ASM Press eBooks · doi:10.1128/9781555815523.ch9 · Cited by 5
Treatment Options for Mucormycosis
Miceli, M. H., & Kauffman, C. A. (2015) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-015-0050-8 · Cited by 5
Current Antifungal Agents for Treatment of Central Nervous System Infections
Coulter, K. S., & Bariola, J. R. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0186-x · Cited by 5
Mucormicosis gastrointestinal en paciente diabético; reporte de un caso y revisión de la literatura
García, C., García, E., Gómez, C., & Castillo, S. A. (2012) · Infectio · doi:10.1016/s0123-9392(12)70035-8 · Cited by 5
Treatment of mucormycosis with liposomal Amphotericin B, posaconazole and deferasirox: A case report
Sıpahı, O. R., Önal, U., Tasbakan, M. I., Yamazhan, T., Arda, B., Pullukçu, H., & Ulusoy, S. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.03.1009 · Cited by 5
“The possible utility of oral iron chelating agent, deferasirox, as an adjunctive therapy for mucormycosis has been evaluated in small studies, with conflicting results [5,6].”
BackgroundResultCombination Therapy for the Treatment of Mucormycosis: Examining the Evidence
Huang, A. M., Nagel, J. L., Crass, R. L., & Nguyen, C. T. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-015-0222-5 · Cited by 5
Ramalingam, K., & Lee, V. (2019) · Nano Biomedicine and Engineering · doi:10.5101/nbe.v11i3.p226-237 · Cited by 5
Saullo, J. H., & Alexander, B. D. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00038-5 · Cited by 5
Current Diagnosis and Management of Mucormycoses
Christoff, J., Galaydick, J., Ramaprasad, C., PITRAK, D. L., & Mullane, K. M. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0008-8 · Cited by 5
“These chelators may be beneficial as therapy for mucormycosis, as indicated by mouse models [28].”
BackgroundMolecular studies on zygomycetes fungi causing opportunistic infections
Papp, T., Nyilasi, I., Csernetics, Á., Galgóczy, L., & Vágvölgyi, C. (2008) · Reviews in Medical Microbiology · doi:10.1097/mrm.0b013e32831a40f9 · Cited by 5
“chelator deferasirox (an iron chelator for treatment of iron overload in transfusion-dependent anaemias) effectively protects mice from zygomycosis through iron starvation [83].”
BackgroundCombination Antifungal Therapy
Ashley, E. D., & Johnson, M. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_10 · Cited by 5
Rajguru, J. R., Desai, R. S., Jadhav, S. D., & Navale, S. D. (2021) · Cited by 4
Ni, T., Chi, X., Wu, H., Xie, F., Bao, J., Wang, J., Ji, Z., Li, L., Wang, X., Yan, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116026 · Cited by 4
Rhizopus oryzae: Genetic Secrets of an Emerging Human Pathogen
Wickes, B. L. (2013) · Soil biology · doi:10.1007/978-3-642-39339-6_11 · Cited by 4
Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report
Önal, U., Tasbakan, M. I., Yamazhan, T., Arda, B., Pullukçu, H., Ulusoy, S., & Sıpahı, O. R. (2016) · Journal of Microbiology and Infectious Diseases · doi:10.5799/ahinjs.02.2016.01.0211 · Cited by 4
Salvage Therapy for the Treatment of Mucormycosis
Patel, A. A., Bork, J. T., & Riedel, D. J. (2021) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-021-00250-z · Cited by 4
Apostolidi, E. A., Gamaletsou, M. N., Arapaki, M. P., Asimakopoulos, J., Diamantopoulos, P. T., Zafeiratou, S., Kofteridis, D. P., Pagoni, M. N., Kotsopoulou, M., Voulgarelis, M., et al. (2023) · Journal of Fungi · doi:10.3390/jof9070748 · Cited by 4
“On the contrary, iron starvation has been shown to induce apoptosis in Mucorales, in vitro and in experimental models [19,20].”
BackgroundFungal infections of the central nervous system
Hamill, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00028-1 · Cited by 4
Opportunistic and systemic fungi
Mitchell, T. G., Verweij, P. E., & Hoepelman, A. I. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-04579-7.00178-7 · Cited by 4
Candel, F. J., Matesanz, M., & Mensa, J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70014-1 · Cited by 4
“Two new iron chelators, deferiprone and deferasirox, show antifungal activity in vitro at concentrations that can be reached in plasma with current dosing schedules [19,20].”
BackgroundAntachopoulos, C., Petraitienė, R., Roilides, E., & Walsh, T. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-35803-6_14 · Cited by 3
Tóth, Z., Farkas, B., Majoros, L., Jakab, Á., Borman, A. M., Varga, I., Tóth, P., & Kovács, R. (2025) · Medical Mycology · doi:10.1093/mmy/myaf116 · Cited by 3
Molecular Mechanisms of Mucormycosis Pathogenesis: Host–Pathogen Interactions and Immune Evasion
Alanazi, A., Ibrahim, M. N. F., Alenezi, M., & Albalawi, W. O. (2026) · Pathogens · doi:10.3390/pathogens15050522 · Cited by 3
“Preclinical research shows that in murine models of mucormycosis, iron chelation with deferasirox decreased fungal burden and increased survival [75].”
Influence of iron on growth and on susceptibility to itraconazole in Sporothrix spp
Hellwig, A. H. D. S., Pagani, D. M., Rios, I. D. S., Ribeiro, A. C., Zanette, R. A., & Scroferneker, M. L. (2020) · Medical Mycology · doi:10.1093/mmy/myaa099 · Cited by 3
Mucormycosis: Prognosis and management
Chakraborty, S., & Chowdhury, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85730-7.00057-6 · Cited by 3
Neuro-Ophthalmology Cases for the Neurologist
Smith, S. V., Amram, A. L., Rodarte, E. M., & Lee, A. G. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.04.005 · Cited by 3
Mucormycosis: Pathogenesis, Diagnosis, and Management
Rauthan, P., & Sharma, D. C. (2021) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v9i3.975 · Cited by 3
Polymer‐Based Antimicrobial Delivery Carriers
(2010) · Wiley eBooks · doi:10.1002/9780470640463.ch11 · Cited by 3
Combined Desferrioxamine (Desferal) and Deferasirox in Children
Molavi, M. A., Poor, S. T., Malesksabet, M., & Abbas, B. (2014) · Cited by 3
Lemhamdi, O., Willems, É., Baron, F., Prijck, B. D., Caers, J., Bouquegneau, A., Guiot, J., Cousin, F., Jadoul, A., Rogister, F., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1715663 · Cited by 2
Cavitary Lung Lesions in a Renal Transplant Recipient
Kempker, J. A., Sheth, A. N., & Kempker, R. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir304 · Cited by 2
Tsoulas, C., Tragiannidis, A., & Groll, A. H. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0166-6 · Cited by 2
Zhou, E.-M., Chen, X.-A., Zhou, M., Xu, L.-Y., Wang, D., Shen, H., & Xu, W. (2024) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2024.105575 · Cited by 2
Kumar, N., Singh, A. K., Pandey, S., Agrawal, S., & Singh, S. (2015) · Egyptian Journal of Oral & Maxillofacial Surgery · doi:10.1097/01.omx.0000464798.32075.d8 · Cited by 2
Cavitary Lung Lesions in a Renal Transplant Patient
(2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir330 · Cited by 2
“Unlike deferoxamine, deferasirox is not used as a siderophore by Mucorales, but instead deprives the organism of iron needed for growth [6].”
BackgroundAugmentation of innate host defenses against opportunistic fungal pathogens
Shoham, S., Roilides, E., & Walsh, T. J. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0024-8 · Cited by 2
Optimisation du traitement préventif et curatif de la mucormycose pulmonaire
Brunet, K. (2020) · theses.fr (ABES) · doi:10.70675/1367c1e7zd412z4f2ez9be3zb15a2d64bb30 · Cited by 2
Role of Deferasirox as an Adjuvant to Parenteral Antifungal Therapy in Invasive Fungal Sinusitis
Chavan, S. S., MEHERE, Y., KHOND, A., & RADHAKRISHNAN, R. (2021) · Egyptian Journal of Ear Nose Throat and Allied Sciences · doi:10.21608/ejentas.2021.70482.1349 · Cited by 1
“In particular, combination therapy resulted in a 100-fold decrease in brain fungal burden, compared with monotherapy and improved survival[11].”
BackgroundTreatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report
Önal, U. (2015) · Journal of Microbiology and Infectious Diseases · doi:10.5799/jmid.328767 · Cited by 1
Reiss, E., Shadomy, H. J., & Lyon, G. M. (2011) · Wiley eBooks · doi:10.1002/9781118101773.ch17a · Cited by 1
Lyons, J. L. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0376-7 · Cited by 1
“Indeed, this connection has been made in those with diabetic ketoacidosis and iron overload states [37].”
BackgroundA Common Fungus, an Unusual (and Deadly) Infection
Tan, S. K., & Aronowitz, P. B. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.005 · Cited by 1
Mucormycosis Presenting as Orbital Cellulitis; A Case Report
Stuart, A. J. (2015) · Advances in Ophthalmology & Visual System · doi:10.15406/aovs.2015.03.00078 · Cited by 1
“Some research has shown certain iron chelators such as desafirox to be protective against mucormycosis in a mice model [14].”
BackgroundCurrent Controversies in the Treatment of Fungal Infections
Pfeiffer, C. D., Perfect, J. R., & Alexander, B. D. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-644-3_27 · Cited by 1
Bronchial Necrosis from Mucormycosis: A Case Report and Review
Heimes, J. K., Zaheer, S., & Wallen, J. M. (2016) · Journal of Pulmonary & Respiratory Medicine · doi:10.4172/2161-105x.1000385 · Cited by 1
“Iron chelators such as deferiprone and deferasirox which lack xenosiderophore activity and have been shown to be protective in animal models of mucormycosis [2,12].”
BackgroundAgents of Mucormycosis (Zygomycosis)
Patterson, T. F., & Sutton, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00248-8 · Cited by 1
Real-Life Challenges to the Use of Antifungal Agents in Hematology Patients
Perissinotti, A. J., & Marini, B. L. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0303-8 · Cited by 1
“High-grade evidence is also lacking to support the use of azole (posaconazole or isavuconazole)/amphotericin B combination therapy, and despite in vitro synergy, iron chelation was shown to be detrimental in a randomized, double-blind, placebo-controlled, phase II trial [66, 67].”
“Mucormycosis” The Emerging Global Threat – A Complete Review
Shabaraya, A. R., & Nypunya, K. (2021) · International Journal of Research and Review · doi:10.52403/ijrr.20210623 · Cited by 1
Krónikus limfocitás leukémiás beteg orbita és szem mucormycosisa
József, G. S., Tajti, B., Fullajtár, B., Sira, Á., & Ilonczai, P. (2022) · Hematológia–Transzfuziológia · doi:10.1556/2068.2022.00144 · Cited by 1
Mucormycosis of the Middle Ear—A Report of a Rare Case
Madhu, M., P., S. D. K., Bhat, V. S., & Srinivas, T. (2023) · Journal of Health and Allied Sciences NU · doi:10.1055/s-0043-1769583 · Cited by 1
Role of Amphotericin B in the Treatment of Mucormycosis
Sachdeva, A., Targhotra, M., Chauhan, M. K., & Chopra, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128272443231221101415 · Cited by 1
Gastrointestinal Mucormycosis: An Elusive, Unusual, and Severe Opportunistic Mycosis.
Adachi, J. A., & Kontoyiannis, D. P. (2009) · PubMed · Cited by 1
Nakazato, G., Fávaro, W. J., & Durán, N. (2021) · doi:10.21467/preprints.330 · Cited by 1
Lax, C., Navarro-Mendoza, M. I., Arques, C. P., Navarro, E., Nicolás, F. E., & Garre, V. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3860385 · Cited by 1
Taleb, M. (2021) · theses.fr (ABES) · doi:10.70675/3fae5636z8e09z46ecza8d8zf84434d2bf14 · Cited by 1
Verlaufsbeobachtung einer rhinozerebralen Zygomykose bei einem nur teilweise complianten Patienten
Gruber, I., & Lackinger, B. (2010) · Spektrum der Augenheilkunde · doi:10.1007/s00717-010-0400-3
“verbessern und die Pilzlast reduzieren [13].”
BackgroundInfluentialKataláz aktivitás vizsgálata a Rhizopus oryzae opportunista patogén járomspórás gombában
Linka, B. (2012) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.1507
Survival in rhinocerebral mucormycosis: Is iron the key?
Bhargava, P. (2007) · Neurology India · doi:10.4103/0028-3886.37101
The role of adjuvant agents in treating fungal diseases
Grim, S. A., & Clark, N. M. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0016-8 · Cited by 1
“In neutropenic mice, deferasirox (Exjade; Novartis, Basel, Switzerland) was found to decrease fungal burden, improve survival, and work synergistically with amphotericin B by reducing available iron to the fungi [ 123 ].”
BackgroundCombination Antifungal Therapy: Is it for everyone and every mycosis?
Graybill, J. R. (2012) · Infectio · doi:10.1016/s0123-9392(12)70022-x
Nyilasi, I. (2008) · SZTE Repository of Dissertations (University of Szeged)
Left Knee Cellulitis in a 61-Year-Old Carpenter
Halloush, R. A., Saeed, Q., & Khasawneh, F. A. (2013) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318278f8b7
“In animal models, combining echinocandins, despite no in vitro activity against Mucorales, or the iron chelator, deferasirox, with lipid polyenes markedly improved survival.(11,12) Posaconazole’s lack of activity against some Mucorales and its variable serum concentration, especially in patients with mucositis and dia…”
BackgroundLIFE-THREATENING CUTANEOUS FUNGAL AND PARASITIC DISEASES
Ramos‐e‐Silva, M., Costanza, C. G., & Carneiro, S. C. D. S. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511778339.014
RHINOCEREBRAL MUCORMYCOSIS: A CASE REPORT
Greffie, E. S., Abay, Z., & Shibiru, H. (2017) · Ethiopian Medical Journal
Lai, Y. (2016) · The Sydney eScholarship Repository (The University of Sydney)
Search for new antimicrobial agents: from old pharmaceuticals to new synthetic compounds
Neves, C. D. S. (2018) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/hz7h-j776
Investigating the impact of polymicrobial interactions on fungal pathogenicity
Kousser, C. (2019) · University of Birmingham Institutional Research Archive (University of Birmingham)
Ataergın, S., & Lazarus, H. M. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-26
Characterization of novel hydrophobic surface binding proteins in Mucor circinelloides
Vaz, A. G. (2021) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10650
“Some of the virulence factors specific to Mucorales are the followings: High-affinity iron permease (FTR1) plays a role in the uptake and transport of iron in Mucorales (Ibrahim et al., 2007).”
BackgroundMethodInfluentialSpórafelszíni fehérjéket kódoló gének jellemzése Mucor circinelloides-ben
Szebenyi, C. (2021) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10708
Gruener, A. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-74103-7_15
Itabangi, H. (2019) · University of Birmingham Institutional Research Archive (University of Birmingham)
Metadata
- Authors
- Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J.
- Affiliations
- University of California, Los Angeles (US)
- Charles River Laboratories (United States) (US)
- National Center for Agricultural Utilization Research (US)
- Corresponding author
- Ibrahim, Ashraf S.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2007-09-04
- Volume
- 117
- Issue
- 9
- Pages
- 2649-2657
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1957543
- OpenAlex
- W2113977119
- Cited by
- 308
- References
- 43
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 21 · 2020: 15 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 12 · 2015: 15 · 2014: 20 · 2013: 23 · 2012: 25
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- National Institute of Allergy and Infectious Diseases (R01 AI63503-01A2, R01AI019990, K08AI060641, AI-063382, R01-AI19990, R21AI064716, R01AI063382, R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- mucormycosis, deferasirox, iron chelation, iron starvation, Mucorales, Rhizopus oryzae, liposomal amphotericin B, antifungal therapy, diabetic ketoacidosis, neutropenia, host inflammatory response, serum iron, adjunctive therapy
- MeSH terms
- Deferasirox, Amphotericin B, Animals, Benzoates, Diabetes Mellitus, Drug Therapy, Combination, Iron, Iron Chelating Agents, Liposomes, Male, Mice, Inbred BALB C, Mucorales, Mucormycosis, Triazoles, Survival Rate, Th1 Cells, Th2 Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.